Modern know-how helps surgeons mitigate dangers of bacterial contamination on orthopaedic implant surfaces in working rooms
Addition of a brand new 4,600-square-foot manufacturing facility in Bridgewater, New Jersey, to its headquarters in Parsippany strengthens Onkos Surgical’s dedication to the area
PARSIPPANY, N.J., Dec. 10, 2025 /PRNewswire/ — Onkos Surgical, a number one supplier of modern options for advanced orthopaedic procedures, has opened the NanoCept Innovation Middle, a brand new facility in Bridgewater Township, NJ.
Positioned within the New Jersey Middle of Excellence Campus, the brand new 4,600-square-foot facility will enable the corporate to deliver a full innovation course of in-house for its flagship NanoCept® Antibacterial Know-how, the primary ever orthopaedic antibacterial coating commercially obtainable on the U.S. market. The product provides a proactive strategy in opposition to intraoperative bacterial contamination, a vital development within the subject of orthopaedic implants. The manufacturing capability enlargement will enable the corporate to fulfill a rising demand for the NanoCept know-how from surgeons and hospitals.
“Onkos is proud to have labored with the FDA to deliver to market the primary antibacterial coating know-how. The opening of the NanoCept Innovation Middle marks one other necessary milestone in our firm’s journey,” mentioned Patrick Treacy, Founder and CEO. “This funding will enable us to get this groundbreaking know-how into the arms of extra surgeons, quicker, and it places us ready to assist extra sufferers with advanced orthopaedic situations.”
“I’m excited by Onkos’ dedication to deliver this know-how to extra implants and in the end to extra sufferers,” mentioned Steven Gitelis, MD, Director of Rush College/MD Anderson’s Orthopaedic Oncology Program and Chief Medical Officer of Onkos. “This can be a distinctive know-how that arms us, as surgeons, with a strong resolution to assist mitigate the intense difficulty of micro organism within the working room.”
Onkos Surgical’s dedication to the New Jersey area
Opening the brand new facility in Bridgewater underscores Onkos Surgical’s robust dedication to the area. The NanoCept Innovation Middle will make use of a workforce of chemists, engineers, and technicians within the new facility to steer its innovation operations. The corporate’s headquarters are positioned at 77 East Halsey Street in Parsippany, NJ.
“The opening of the NanoCept Innovation Middle in Bridgewater exemplifies the cutting-edge innovation that defines New Jersey’s seventh Congressional District,” mentioned Congressman Tom Kean, Jr. “Developments like these being pursued by Onkos Surgical have the potential to drive significant progress in affected person care and increase prospects in trendy drugs. Congratulations to Onkos on this outstanding milestone.”
Onkos Surgical held a ribbon slicing ceremony to have a good time the opening of the NanoCept Innovation Middle on December 9, 2025. Amongst company had been Steven Gitelis, MD, Director of Rush College/MD Anderson’s Orthopaedic Oncology Program and Chief Medical Officer of Onkos; Michael Kirsh, Township Councilman, Township of Bridgewater; Althea D. Ford, Vice President, Authorities Affairs, New Jersey Enterprise & Business Affiliation; Erin D’Auria, District Director for Congressman Tom Keane Jr. representing the 7th District of New Jersey; John Coelho, Life Sciences Strategic Innovation Senior Advisor at New Jersey Financial Growth Authority (NJEDA); and Jessica Paolini, Director, Financial Growth for Somerset County, Workplace of the County Administrator.
About Onkos Surgical
Onkos Surgical is a frontrunner in modern options for advanced orthopaedic situations. With our novel product portfolio, surgeons are higher knowledgeable about patient-specific medical challenges and are capable of plan and implement extra exact reconstructions. Our personalised strategy helps improved affected person outcomes and experiences utilizing the newest improvements in antibacterial implant coatings, digital surgical planning, 3D anatomic modeling and printing, implant design, and workflow optimization. Greater than 350 of the main educational medical establishments within the US select Onkos for his or her advanced revision and tumor orthopaedic circumstances. The NanoCept know-how is designed to guard orthopaedic implants throughout surgical procedure, previous to implantation. The NanoCept know-how’s effectiveness has not been proven in human medical trials to stop or scale back an infection charges. For extra data on Onkos Surgical and its services and products, please go to www.onkossurgical.com/nanocept.
Ahead Wanting Statements:
Sure statements made on this launch that aren’t statements of historic or present details are forward-looking statements which contain identified and unknown dangers, uncertainties and different components that will trigger the precise outcomes, efficiency, or achievements of the corporate to be materially totally different from historic outcomes or from any future outcomes or projections expressed or implied by such forward-looking statements. In lots of circumstances, forward-looking statements will be recognized by phrases reminiscent of “future,” “believes,” “expects,” “might,” “will,” “ought to,” “potential,” “estimates,” “intends,” “anticipates” or “plans” or the damaging of those phrases or different comparable terminology. Ahead-looking statements are based mostly upon administration’s beliefs, assumptions and present expectations however are topic to identified and unknown dangers and uncertainties together with, with out limitation, the likelihood that post-market medical outcomes could also be inconsistent with the in-vitro preclinical take a look at outcomes and the potential for brand spanking new applied sciences and procedures to disrupt market demand. Though administration believes that the expectations mirrored within the forward-looking statements are cheap, forward-looking statements will not be, and shouldn’t be relied upon as a assure of future efficiency or outcomes. The forward-looking statements included are made solely on the date of this launch. The corporate assumes no obligation to replace any data or forward-looking assertion contained herein, save for any data required to be disclosed by regulation.
Media Contact:
Alyssa Paldo
Vice-President, Media Relations Specialist
FINN Companions
[email protected]
847.791.8085
SOURCE ONKOS SURGICAL
Leave a Reply